VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

An Analysis of Bevacizumab or Cetuximab for CRC

Tanios Bekaii-Saab, MD
Published Online: Aug 13,2014
Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

Read more about the treatment of CRC > >


Clinical Articles

An Analysis of Bevacizumab or Cetuximab for CRC
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.